Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expression

Tu,Min; Liu,Xian; Han,Bei; Ge,Qianqian; Li,Zhanjun; Lu,Zipeng; Wei,Jishu; Song,Guoxin; Cai,Baobao; Lv,Nan; Jiang,Kuirong; Wang,Shui; Miao,Yi; Gao,Wentao

doi:10.3892/mmr.2014.2317

Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expression

Authors:
- Min Tu
- Xian Liu
- Bei Han
- Qianqian Ge
- Zhanjun Li
- Zipeng Lu
- Jishu Wei
- Guoxin Song
- Baobao Cai
- Nan Lv
- Kuirong Jiang
- Shui Wang
- Yi Miao
- Wentao Gao
View Affiliations

Affiliations: Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Department of Endocrinology, Nanjing Children's Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210008, P.R. China, Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China
Published online on: June 10, 2014 https://doi.org/10.3892/mmr.2014.2317
Pages: 663-669
Copyright: © Tu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vasohibin‑2 (VASH2) is an angiogenic factor, and has been previously reported to be a cancer‑related gene, with cytoplasmic and karyotypic forms. In the current study VASH2 expression in human breast cancer tissue and adjacent non‑cancerous tissue was investigated with immunohistochemistry. MCF‑7 and BT474 human breast cancer cells were transfected with lentiviral constructs to generate in vitro VASH2 overexpression and knockdown models. In addition, BALB/cA nude mice were inoculated subcutaneously with transfected cells to generate in vivo models of VASH2 overexpression and knockdown. The effect of VASH2 on cell proliferation was investigated using a bromodeoxyuridine assay in vitro and immunohistochemistry of Ki67 in xenograft tumors. Growth factors were investigated using a human growth factor array, and certain factors were further confirmed by an immunoblot. The results indicated that the expression level of cytoplasmic VASH2 was higher in breast cancer tissues with a Ki67 (a proliferation marker) level of ≥14%, compared with tissues with a Ki67 level of <14%. VASH2 induced proliferation in vitro and in vivo. Four growth factors activated by VASH2 were identified as follows: Fibroblast growth factor 2 (FGF2), growth/differentiation factor‑15 (GDF15), insulin‑like growth factor‑binding protein (IGFBP)3 and IGFBP6. FGF2 and GDF15 may contribute to VASH2‑induced proliferation. The current study identified a novel role for VASH2 in human breast cancer, and this knowledge suggests that VASH2 may be a novel target in breast cancer treatment.

View Figures

View References

1	Sato Y: The vasohibin family: a novel family for angiogenesis regulation. J Biochem. 153:5–11. 2013. View Article : Google Scholar : PubMed/NCBI
2	Shibuya T, Watanabe K, Yamashita H, Shimizu K, Miyashita H, Abe M, Moriya T, Ohta H, Sonoda H, Shimosegawa T, Tabayashi K and Sato Y: Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol. 26:1051–1057. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T and Sato Y: Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 113:4810–4818. 2009. View Article : Google Scholar : PubMed/NCBI
4	Xue X, Gao W, Sun B, Xu Y, et al: Vasohibin 2 is transcriptionally activated and promotes angiogenesis in hepatocellular carcinoma. Oncogene. 32:1724–1734. 2013. View Article : Google Scholar : PubMed/NCBI
5	Takahashi Y, Koyanagi T, Suzuki Y, Saga Y, Kanomata N, Moriya T, Suzuki M and Sato Y: Vasohibin-2 expressed in human serous ovarian adenocarcinoma accelerates tumor growth by promoting angiogenesis. Mol Cancer Res. 10:1135–1146. 2012. View Article : Google Scholar : PubMed/NCBI
6	Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M and Sato Y: In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer. Cancer Sci. 104:1705–1710. 2013. View Article : Google Scholar : PubMed/NCBI
7	Sun J, Tu M, Han B, Xue X, et al: Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization. Int J Oncol. 43:255–261. 2013.PubMed/NCBI
8	Beresford MJ, Wilson GD and Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res. 8:2162006. View Article : Google Scholar : PubMed/NCBI
9	Lopez F, Belloc F, Lacombe F, Dumain P, Reiffers J, Bernard P and Boisseau MR: Modalities of synthesis of Ki67 antigen during the stimulation of lymphocytes. Cytometry. 12:42–49. 1991. View Article : Google Scholar : PubMed/NCBI
10	Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ and Ramaekers FC: Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase. J Cell Sci. 92:123–130. 1989.
11	Heidebrecht HJ, Buck F, Haas K, Wacker HH and Parwaresch R: Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the ‘Ki-67’ proteins. Cell Prolif. 29:413–425. 1996.PubMed/NCBI
12	Allred DC, Mohsin SK and Fuqua SA: Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer. 8:47–61. 2001. View Article : Google Scholar : PubMed/NCBI
13	Rudas M, Neumayer R, Gnant MF, Mittelböck M, Jakesz R and Reiner A: p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ carcinomas of the breast. Eur J Cancer. 33:39–44. 1997. View Article : Google Scholar
14	Shoker BS, Jarvis C, Davies MP, Iqbal M, Sibson DR and Sloane JP: Immunodetectable cyclin D(1)is associated with oestrogen receptor but not Ki67 in normal, cancerous and precancerous breast lesions. Br J Cancer. 84:1064–1069. 2001. View Article : Google Scholar : PubMed/NCBI
15	Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexiou I, Pateras I, Konstantoudakis K and Stamatakos M: Correlation between Ki67 and breast cancer prognosis. Oncology. 84:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
16	Sporn MB and Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med. 303:878–880. 1980. View Article : Google Scholar : PubMed/NCBI
17	Witsch E, Sela M and Yarden Y: Roles for growth factors in cancer progression. Physiology (Bethesda). 25:85–101. 2010. View Article : Google Scholar : PubMed/NCBI
18	Chandler LA, Sosnowski BA, Greenlees L, Aukerman SL, Baird A and Pierce GF: Prevalent expression of fibroblast growth factor (FGF) receptors and FGF2 in human tumor cell lines. Int J Cancer. 81:451–458. 1999. View Article : Google Scholar : PubMed/NCBI
19	Yin T, Cho SJ and Chen X: RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability. J Biol Chem. 288:23680–23686. 2013. View Article : Google Scholar : PubMed/NCBI
20	Chitnis MM, Yuen JS, Protheroe AS, Pollak M and Macaulay VM: The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
21	Bach LA, Fu P and Yang Z: Insulin-like growth factor-binding protein-6 and cancer. Clin Sci (Lond). 124:215–229. 2013. View Article : Google Scholar : PubMed/NCBI
22	Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA and Yee D: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst. 88:601–606. 1996. View Article : Google Scholar
23	Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng Cn, Lee AV and Yee D: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. Clin Cancer Res. 3:103–109. 1997.
24	Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, et al: IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 4:29–41. 2014.PubMed/NCBI